Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB announces lacosomide results

UCB announces lacosomide results

25th June 2008

UCB has revealed the results of a clinical trial where fibromyalgia syndrome (FMS) was treated using lacosamide.

Initial results from the trial are encouraging but require further analysis, the company said.

The trial was randomised, double-blind and placebo-controlled in order to assess the usefulness and safety of administering 400mg/day lacosamide tablets to patients suffering from symptoms associated with FMS.

Measuring change in average daily pain using an 11-point Likert scale, it was found that there was an effect size of 0.5 in favour of lacosamide versus placebo and the drug was generally very well tolerated.

These results were based on 158 randomised patients.

A decision to start the next phase of trials is due to be made by the end of the year.

Earlier this month, UCB came to an agreement with Otsuka to co-promote UCB’s anti-epiletic drug Keppra (levetiracetam) and its anti-TNF alpha drug Cimzia (certolizumab pegol) in Japan.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.